PALISADE BIO, INC.(PALI)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.7M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
PALI Stock Analysis & AI Quality Score
AI stock analysis and institutional research for PALISADE BIO, INC. (PALI), a Healthcare sector company. PALI is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.7m in revenue. Based on the latest XBRL financial filings (Q1 2026), PALISADE BIO, INC. reports net income of $-9.6M, free cash flow of $-3.9M. Top institutional holders of PALI by reported 13-F value include B Group,, JANUS HENDERSON GROUP PLC, Octagon Capital Advisors, based on the most recent SEC filings. PALI trades on the Nasdaq exchange and files with the SEC under CIK 1357459. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PALI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PALISADE BIO, INC. directly from SEC EDGAR.
Revenue
Q1 2026
$0.00
Net Income
Q1 2026
$-9.6M
Free Cash Flow
Q1 2026
$-3.9M
Get alerted when PALI's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for PALISADE BIO, INC. including:
Top Institutional Holders of PALI
B Group, Inc.
$20.0M11,414,285 shJANUS HENDERSON GROUP PLC
$18.8M10,689,452 shOctagon Capital Advisors LP
$18.0M10,276,317 shPERCEPTIVE ADVISORS LLC
$15.6M8,928,149 shAMERIPRISE FINANCIAL INC
$15.2M8,711,385 shCommodore Capital LP
$12.6M7,181,062 shRA CAPITAL MANAGEMENT, L.P.
$12.5M7,124,116 shFRANKLIN RESOURCES INC
$10.1M5,785,189 shGOLDMAN SACHS GROUP INC
$9.4M5,373,951 shEversept Partners, LP
$8.7M4,987,499 sh
| Fund | Value | Shares |
|---|---|---|
| B Group, Inc. | $20.0M | 11,414,285 |
| JANUS HENDERSON GROUP PLC | $18.8M | 10,689,452 |
| Octagon Capital Advisors LP | $18.0M | 10,276,317 |
| PERCEPTIVE ADVISORS LLC | $15.6M | 8,928,149 |
| AMERIPRISE FINANCIAL INC | $15.2M | 8,711,385 |
| Commodore Capital LP | $12.6M | 7,181,062 |
| RA CAPITAL MANAGEMENT, L.P. | $12.5M | 7,124,116 |
| FRANKLIN RESOURCES INC | $10.1M | 5,785,189 |
| GOLDMAN SACHS GROUP INC | $9.4M | 5,373,951 |
| Eversept Partners, LP | $8.7M | 4,987,499 |
More Healthcare Companies
View all Healthcare →Put PALI on your watchlist
Track score changes the day PALISADE BIO, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is PALI a good stock to buy?
13F Pro's AI-powered analysis of PALISADE BIO, INC. (PALI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PALI are available on the PALI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own PALI?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PALI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of PALISADE BIO, INC.'s investment landscape.